Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2

6 Oct 2022

Abstract excerpt

Monoclonal antibody therapy has played an important role against SARS-CoV-2. Strategies to deliver functional, antibody-based therapeutics with improved in vivo durability are needed to supplement current efforts and reach underserved populations. Here, we compare recombinant mAbs COV2-2196 and COV2-2130, which compromise clinical cocktail Tixagevimab/Cilgavimab, with optimized nucleic acid-launched forms....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36202799
DOI: 10.1038/s41467-022-33309-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2PMID 36202799Read ↗

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsSemantic proximity Read ↗

Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escapeSemantic proximity Read ↗

Structure and sequence engineering approaches to improve in vivo expression of nucleic acid-delivered antibodies.Semantic proximity Read ↗

Integrated technology platform for accelerated discovery of antiviral antibody therapeuticsSemantic proximity Read ↗

Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimensSemantic proximity Read ↗

An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.Semantic proximity Read ↗

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.Semantic proximity Read ↗

MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection <i>in vitro</i> and in a hamster model of COVID-19Semantic proximity Read ↗

Interrogating antiviral antibody responses with multiplexed, high-throughput serum assaysSemantic proximity Read ↗

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Semantic proximity Read ↗

Dissecting human monoclonal antibody responses from mRNA- and protein-based XBB.1.5 COVID-19 monovalent vaccinesSemantic proximity Read ↗

Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD-20 therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.